Department of Respiratory Medicine, Yantaishan Hospital, Yantai, China.
Department of Clinical Laboratory, Jinan Zhangqiu District Hospital of TCM, Jinan, China.
J Biol Regul Homeost Agents. 2020 May-Jun;34(3):825-835. doi: 10.23812/20-11-A-34.
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases. MicroRNAs (miRNAs/miRs) have been reported to play significant roles in the progression of human tumors, however, the expression and biological role of miR-23b in NSCLC remains elusive. Underexpression of miR-23b was detected in NSCLC tissues in comparison with the matched para-carcinoma tissues. The clinical value of miR-23b was analyzed, and the findings showed that miR-23b expression was negatively correlated with poor overall survival and malignant clinicopathologic characteristics of NSCLC patients. Furthermore, functional assays demonstrated that overexpression of miR-23b inhibited NSCLC cell viability, invasion and migration. Luciferase reporter assay and qRT-PCR revealed that RUNX2 was a functional target of miR-23b. The elevated expression of RUNX2 was positively correlated with overall survival of NSCLC patients. Additionally, Western blot analysis indicated that EMT and Wnt/β-catenin pathways were blocked by the upregulation of miR-23b. Taken together, these data demonstrated that dysregulation of miR-23b/RUNX2 signal may be a novel therapeutic target for the treatment of NSCLC.
非小细胞肺癌（NSCLC）约占所有肺癌病例的 85%。已有研究报道，microRNAs（miRNAs/miRs）在人类肿瘤的进展中发挥着重要作用，然而，miR-23b 在 NSCLC 中的表达和生物学作用仍不清楚。与配对的癌旁组织相比，NSCLC 组织中检测到 miR-23b 的表达下调。分析了 miR-23b 的临床价值，结果表明 miR-23b 的表达与 NSCLC 患者总体生存率差和恶性临床病理特征呈负相关。此外，功能分析表明，miR-23b 的过表达抑制了 NSCLC 细胞的活力、侵袭和迁移。荧光素酶报告基因检测和 qRT-PCR 显示，RUNX2 是 miR-23b 的功能靶标。RUNX2 的高表达与 NSCLC 患者的总体生存率呈正相关。此外，Western blot 分析表明，miR-23b 的上调阻断了 EMT 和 Wnt/β-catenin 通路。综上所述，这些数据表明，miR-23b/RUNX2 信号的失调可能是治疗 NSCLC 的一种新的治疗靶点。
